First patients dosed with Alder's lead migraine candidate, ALD403. Read the story.

Now recruiting: Proof-of-concept trial for patients with frequent episodic migraines. Learn more.


Alder wins 2013 Innovation in Biopharmaceuticals Award from Seattle Business Magazine. Read the story.


  
Fact
On average, it takes 12 months to generate a commercial antibody strain using mammalian cell cultures. Alder’s yeast-based cultures take about five weeks.
Fact
The cost of producing mammalian cell cultures is US$300 to $1,000 per gram. Alder’s microbial cultures cost a fraction of this amount.
Fact
Over 75% of antibody manufacturing capacity is held by a limited number of companies. Alder provides an alternative manufacturing process that avoids this bottleneck.
Fact
Abbott Laboratories' Humira® is currently the only FDA-approved antibody that can be self-administered. Alder's antibody discovery technologies will allow any company to identify the unique antibodies that can be self-administered by patients.
Fact
2.5 million people in the United States suffer from rheumatoid arthritis. Half of these patients get no relief whatsoever from current drug therapies.
Fact
Nearly one-third of all cancer patients experience overwhelming fatigue. The condition is left untreated by three in four caregivers due to a lack of effective therapies.
Fact
Approximately 40% of cancer patients are anemic. A growing body of clinical evidence suggests that treating anemia for these millions of cancer sufferers can improve both quality of life and clinical outcomes.
Fact
Aglycosylated antibodies such as ALD518 avoid effector function dependent pathways, potentially leading to medicines with superior safety and immune-response profiles.
Fact
ALD518 inhibits the function of IL-6, a pro-inflammatory cytokine. There is currently no approved therapeutic that works by this same novel mechanism of action targeting the IL-6 ligand.
Fact
According to Datamonitor, global sales of antibody-based therapeutics reached $32.2 billion in 2008 and are forecast to reach $58 billion in 2014, an increase of 10.3% per year.